Hostname: page-component-586b7cd67f-l7hp2 Total loading time: 0 Render date: 2024-11-26T04:01:25.510Z Has data issue: false hasContentIssue false
  • English
  • Français

Prevention of Fungal Infections in Hematology Patients

Published online by Cambridge University Press:  02 January 2015

John Philpott-Howard
John Philpott-Howard*
Affiliation:
From the Dulwich Public Health Laboratory and Medical Microbiology, Kings College School of Medicine and Dentistry, London, United Kingdom
*
King's College School of Medicine and Dentistry, Bessemer Rd, London SE5 9PJ, UK
Get access Rights & Permissions [Opens in a new window]

Abstract

Endogenous infections such as candidiasis can be minimized by oral fluconazole prophylaxis, although oral or intravenous amphotericin, or itraconazole, are suitable for certain patients. Exogenous fungal infections most commonly are transmitted by the airborne route, but the benefits of high-efficiency particulate air-filtered room air probably are diminishing as broad-spectrum prophylaxis against Aspergillus species and other fungi improves. However, high-risk environmental sources such as construction work always must be avoided near neutropenic patients. Reactivation of quiescent pulmonary Aspergillus infection can be prevented by surgical resection during remission, or by systemic amphotericin prophylaxis during subsequent neutropenic episodes.

Type
From the Fourth International Conference on the Prevention of Infection
Information
Infection Control & Hospital Epidemiology , Volume 17 , Issue 8 , August 1996 , pp. 545 - 551
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1996

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. Schimpff, SC. Infections in the cancer patient-diagnosis, prevention and treatment. In: Mandell, GL, Bennett, JE, Dolin, R, eds. Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1994:2666–2674.Google Scholar
2. Morrison, VA, Haake, RJ, Weisdorf, DJ. Non-Candida fungal infections after bone marrow transplantation: risk factors and outcome. Am J Med 1994;96:497–503.Google Scholar
3. Chandrasekar, PH, Weinmann, A, Shearer, C, Bone Marrow Transplant Team. Autopsy-identified infections among bone marrow transplant recipients: a clinicopathologic study of 56 patients. Bone Marrow Transplant 1995;16:675–681.Google Scholar
4. Rosetti, F, Brawner, DL, Bowden, R, et al. Fungal liver infection in marrow transplant recipients: prevalence at autopsy, predisposing factors, and clinical features. Clin Infect Dis 1995;20:801–811.Google Scholar
5. Walsh, TJ, Hiemenez, J, Pizzo, PA. Editorial response: evolving risk factors for invasive fungal infections-all neutropenic patients are not the same. Clin Infect Dis 1994;18:793–798.Google Scholar
6. Wiley, JM, Smith, N, Leventhal, BG, et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol 1990;8:280–286.Google Scholar
7. American Society of Clinical Oncology. Recommendations for the use of hematopoietic colony-stimulating factors: evidence-based, clinical practice guidelines. J Clin Oncol 1994;12:2471–2508.Google Scholar
8. Bochud, P-Y, Eggiman, P, Calandra, T, Van Melle, G, Saghafi, L, Francioli, P. Bacteremia due to viridans streptococcus in neutropenic patients with cancer: clinical spectrum and risk factors. Clin Infect Dis 1994;18:25–31.Google Scholar
9. O'Donnell, MR, Schmidt, GM, Tegtmeir, BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin in high-risk patients. J Clin Oncol 1994;12:827–834.Google Scholar
10. Barnes, RA. Immunotherapy and immunoprophylaxis in bone marrow transplantation. J Hosp Infect 1995;30(suppl):223–231.Google Scholar
11. Tuan, IZ, Dennison, D, Weisdorf, DJ. Pneumocystis carinii pneumonitis following bone marrow transplantation. Bone Marrow Transplant 1992;10:267–272.Google Scholar
12. Nucci, M, Schechter, M, Spector, N, et al. Antibiotic regimen as an independent risk factor for disseminated fungal infections in neutropenic patients in Brazil. Trans R Soc Trop Med Hyg 1995;89:107–110.CrossRefGoogle ScholarPubMed
13. Karabinis, A, Hill, C, Leclercq, B, Tancrede, C, Baume, D, Andremont, A. Risk factors for candidemia in cancer patients: a case-control study. J Clin Microbiol 1988;26:429–432.Google Scholar
14. McNeil, MM. Candida. In: Mayhall, CG, ed. Hospital Epidemiology and Infection Control. Baltimore, MD: Williams & Wilkins; 1996:408–419.Google Scholar
15. Reagan, DR, Pfaller, MA, Hollis, RJ, Huston, B, Wenzel, RP. Characterization of the sequence of colonization and nosocomial candidemia using DNA fingerprinting and a DNA probe. J Clin Microbiol 1990;28:2733–2738.Google Scholar
16. Wey, SB, Mori, M, Pfaller, MA, Woolson, RF, Wenzel, RP. Hospital acquired candidemia: attributable mortality and excess length of stay. Arch Intern Med 1988;148:2642–2645.Google Scholar
17. Bross, J, Talbot, GH, Maislin, G, Jurwitz, S, Stron, BL. Risk factors for nosocomial candidemia: a case-control study in adults without leukemia. Am J Med 1989;87:614–620.CrossRefGoogle ScholarPubMed
18. Bodey, GP, Rosenbaum, B. Effect of prophylactic measures on the microbial flora of patients in protected environment units. Medicine 1974;53:209–228.Google Scholar
19. DeGregorio, MW, Lee, WMF, Ries, CA. Candida infections in patients with acute leukemia: ineffectiveness of nystatin prophylaxis and relationship between oropharyngeal and systemic candidiasis. Cancer 1982;50:2780–2784.Google Scholar
20. Buchanan, AG, Riben, PD, Rayner, EN, Parker, SE, Ronald, AR, Louie, TJ. Nystatin prophylaxis of fungal colonization and clinical outcome. Clin Invest Med 1985;8:139–147.Google Scholar
21. Philpott-Howard, J, Wade, J, Mufti, G, Brammer, K, Ehninger, G. Randomized comparison of oral fluconazole vs. oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. JAntimicrob Chemother 1993;31:973–984.Google Scholar
22. Flynn, PM, Cunningham, CK, Kerkering, T, et al. Oropharyngeal candidiasis in immunocompromised children: a randomized, multicenter study of orally administered fluconazole suspension versus nystatin. J Pediatr 1995;127:322–328.CrossRefGoogle ScholarPubMed
23. Goodman, JL, Winston, DJ, Greenfield, RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845–851.Google Scholar
24. Ellis, ME, Clink, H, Ernst, P, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with hematological malignancies and bone marrow transplants. Eur J Clin Microbiol Infect Dis 1994;13:3–11.Google Scholar
25. Rex, JH, Rinaldi, MG, Pfaller, MA. Resistance of Candida species to fluconazole. Antimicrob Agents Chemother 1995;39:1–8.Google Scholar
26. Slavin, MA, Osborne, B, Adams, R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation. A prospective, randomized, double blind study. J Infect Dis 1995;171:1545–1552.Google Scholar
27. O'Donnell, MR, Schmidt, GM, Tegtmeier, BR, et al. Prediction of systemic fungal infection in allogeneic marrow recipients: impact of amphotericin prophylaxis in high-risk patients. J Clin Oncol 1994;12:827–834.Google Scholar
28. Schaffner, A, Schaffner, M. Effect of prophylactic fluconazole on the frequency of fungal infections, amphotericin B use, and health care costs in patients undergoing intensive chemotherapy for hematologic neoplasias. J Infect Dis 1995;172:1035–1041.CrossRefGoogle ScholarPubMed
29. Winston, DJ, Chandrasekar, PH, Lazarus, HM, et al. Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial. Ann Intern Med 1993;118:495–503.Google Scholar
30. Pfaller, MA. Epidemiology of candidiasis. J Hosp Infect 1995;30(suppl):329–338.Google Scholar
31. Wingard, JR, Merz, WG, Rinaldi, MG, et al. Increase in Candida krusei infections among patients with bone marrow transplant and neutropenia treated prophylactically with fluconazole. N Engl J Med 1991;325:1274–1277.Google Scholar
32. Stewart, A, Powles, R, Hewetson, M, Antrum, J, Richardson, C, Mehta, J. Costs of antifungal prophylaxis after bone marrow transplantation. Pharmaco Economics 1995;8:350–361.Google Scholar
33. Grant, SM, Clissold, SP. Itraconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in superficial and systemic mycoses. Drugs 1989;37:310–344.Google Scholar
34. Walsh, TJ, Lee, JW. Prevention of invasive fungal infections in patients with neoplastic disease. Clin Infect Dis 1993;17(suppl 2):468S–480S.Google Scholar
35. Winston, DJ. Prophylaxis and treatment of infection in the bone marrow transplant recipient. Curr Clin Top Infect Dis 1993;13:293–321.Google ScholarPubMed
36. Vreugdenhil, G, Van-Dijke, BJ, Donnelly, JP. Efficacy of itraconazole in the prevention of fungal infections among neutropenic patients with hematologic malignancies and intensive chemotherapy. A double blind, placebo controlled study. Leuk Lymphoma 1993;11:353–358.Google Scholar
37. Working Party of the British Society of Antimicrobial Chemotherapy. Chemoprophylaxis for candidosis and aspergillosis in neutropenia and transplantation: a review and recommendations. J Antimicrob Chemother 1993;32:5–21.Google Scholar
38. Dankner, WM, Spector, SA, Fierer, J, et al. Malassezia fungemia in neonates and adults: complication of hyperalimentation. Rev Infect Dis 1987;9:743–753.Google Scholar
39. Garaventa, A, Rondelli, R, Castagnola, E, et al for the Italian Association of Pediatric Hematology-Oncology BMT Group. Fatal pneumopathy in children after bone marrow transplantation-report from the Italian Registry. Bone Marrow Transplant 1995;16:669–674.Google Scholar
40. Ioannidis, JPA, Cappelleri, JC, Skolnik, PR, Lau, J, Sacks, HS. A meta-analysis of the relative efficacy and toxicity of Pneumocystis carinii prophylactic regimens. Ann Intern Med 1996;156:177–188.Google Scholar
41. Burnie, JP. Candida and hands. J Hosp Infect 1986;8:1–4.Google Scholar
42. van Belkum, A, Melchers, W, de Pauw, BE, Scherer, S, Quint, W, Meis, J. Genotypic characterization of sequential Candida albicans isolates from fluconazole-treated neutropenic patients. J Infect Dis 1994;169:1062–1070.Google Scholar
43. Weems, JJ Jr. Candida parapsilosis: epidemiology, pathogenicity, clinical manifestations, and antimicrobial susceptibility. Clin Infect Dis 1992;14:756–766.CrossRefGoogle ScholarPubMed
44. Strausbaugh, LJ, Sewell, DL, Ward, TT, Pfaller, MA, Heitzman, T, Tjoelker, R. High frequency of yeast carriage on hands of hospital personnel. J Clin Microbiol 1994;32:2299–2300.Google Scholar
45. Darbord, JC, Vincent, F, Boutron, L, Goury, V, Guyomard, S. Susceptibility of Torulopsis glabrata in the presence of six antifungal agents determined by comparison of growth at several pHs. Appl Environ Microbiol 1987;53:593–595.CrossRefGoogle ScholarPubMed
46. Scott, EM, Gorman, SP, McGrath, SJ. An assessment of the fungicidal activity of antimicrobial agents used for hard-surface and skin disinfection. J Clin Hosp Pharm 1986;11:199–205.Google Scholar
47. Hay, RJ, Clayton, YM, Goodley, JM. Fungal aerobiology: how, when, and where? J Hosp Infect 1995;30(suppl):352–357.Google Scholar
48. Arnow, PM, Sadigh, M, Costas, C, et al. Endemic and epidemic aspergillosis associated with in-hospital replication of Aspergillus organisms. J Infect Dis 1991;164:998–1002.Google Scholar
49. Sheretz, RJ, Belani, A, Kamer, BS, et al. Impact of air filtration on nosocomial Aspergillus infections. Unique risk of bone marrow transplant recipients. Am J Med 1987;83:709–718.CrossRefGoogle Scholar
50. Barnes, RA, Rogers, TR. Control of an outbreak of nosocomial aspergillosis by laminar air-flow isolation. J Hosp Infect 1989;14:89–94.Google Scholar
51. Pannuti, CS. Hospital environment for high-risk patients. In: Wenzel, RP, ed. Prevention and Control of Nosocomial Infection. 2nd ed. Baltimore, MD: Williams & Wilkins; 1993:365–384.Google Scholar
52. Fenelon, LE. Protective isolation: who needs it? J Hosp Infect 1995;30(suppl):218–222.Google Scholar
53. Philpott-Howard, JN, Casewell, MW. Hospital Infection Control: Policies and Practical Procedures. London, UK: WB Saunders;1994:81–84.Google Scholar
54. De-Bock, R, Gyssens, I, Peetermans, M, Nolard, N. Aspergillus in pepper. Lancet 1989;ii:331–332.Google Scholar
55. Vargas, S, Hughes, WT, Giannini, MA. Aspergillus in pepper. Lancet 1990;336:881.Google Scholar
56. Riley, DK, Pavia, AT, Beatty, PG, et al. The prophylactic use of low-dose amphotericin B in bone marrow transplant patients. Am J Med 1994;97:509–514.Google Scholar
57. Bodey, GP, Anaissie, EJ, Elting, LS, Estey, E, O'Brien, S, Kantarjian, H. Antifungal prophylaxis during remission induction therapy for acute leukemia: fluconazole versus intravenous amphotericin B. Cancer 1994;73:2099–2106.Google Scholar
58. Jeffery, GM, Beard, ME, Ikram, RB. Intranasal amphotericin B reduces the frequency of invasive aspergillosis in neutropenic patients. Am J Med 1991;90:685–692.Google Scholar
59. Graybill, JR, Najvar, LK, Holmberg, JD, Luther, MF. Fluconazole, D0870, and flucytosine treatment of disseminated Candida tropicalis infections in mice. Antimicrob Agents Chemother 1995;39:924–929.Google Scholar
60. Wardle, HM, Law, D, Moore, CB, Mason, C, Denning, DW. In vitro activity of D0870 compared with those of other azoles against fluconazole-resistant Candida species. Antimicrob Agents Chemother 1995;39:868–871.Google Scholar
61. Debono, M, Gordee, RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol 1994;48:471–497.Google Scholar
62. Martino, P, Raccah, R, Gentile, G, Venditti, M, Girmenia, C, Mandelli, F. Aspergillus colonization of the nose and pulmonary aspergillosis in neutropenic patients: a retrospective study. Haematologica 1989;74:263–265.Google Scholar
63. Riley, DK, Pavia, AT, Beatty, PG, Denton, D, Carroll, KC. Surveillance cultures in bone marrow transplant recipients: worthwhile or wasteful? Bone Marrow Transplant 1995;15:469–473.Google Scholar
64. Ferretti, GA, Ash, RC, Brown, AT, Parr, MD, Romond, EH, Lillich, TT. Control of oral mucositis and candidiasis in marrow transplantation: a prospective double-blind trial of chlorhexidine digluconate oral rinse. Bone Marrow Transplant 1988;3:483–493.Google Scholar
65. McWhinney, PH, Kibbler, CC, Hamon, MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993;17:397–404.Google Scholar
66. Tavares, D, Ferreira, P, Vilanova, M, Videira, A, Arala-Chaves, M. Immunoprotection against systemic candidiasis in mice. Int Immunol 1995;7:785–796.Google Scholar
67. Han, Y, Cutler, JE. Antibody response that protects against disseminated candidiasis. Infect Immun 1995;63:2714–2719.Google Scholar
68. Polonelli, L, Poulain, D, Cole, GT. New strategies in vaccination against fungal infections. J Med Vet Mycol 1994;32(suppl 1):105–112.Google Scholar